Analysts expect over 2023 revenue increase Biocartis

Tomorrow the French company Biocartis will publish its past quarters results. Over the current book year the company from could achieve a revenue around 71.1 million euros (consensus estimates). This is quite more than 2022's revenue of 57.48 million euros.

Historical revenues and results Biocartis plus estimates 2023

The analysts expect for 2023 a net loss of 39 million euros. For this year the majority of the analysts, consulted by press agency Thomson Reuters, expects a loss per share of 20 cent. So the price/earnings-ratio equals -3.6.

Analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies is a good 3.55 percent.

Based on the current number of outstanding shares Biocartis 's market capitalization 47.43 million euros.

Historical stock prices Biocartis past 17 years

At 9.00 the stock trades 0 percent lower at 0.72 euros.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.